TG Therapeutics' stock rose 15% since my November buy recommendation, driven by Briumvi's strong performance and strategic ...

Hinge Bio, Inc., a privately-held biotechnology company, today announced the close of a Series A’ financing led by Point72. Joining Point72 are Ridgeback Capital, InVivium Capital, and Lightswitch ...

The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

The five-year-old Waltham, Massachusetts-based company is developing a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, called obexelimab, which is in a phase 3 trial as a treatment ...

After hours: January 16 at 4:20:03 PM EST Loading Chart for CGEM ...

Discover why Incyte's strong growth trajectory and upcoming product launches make it an attractive investment with a ...

Incyte will provide an update on commercial growth, clinical progress and significant 2025 catalysts during a presentation today at 10:30 a.m. PT at the 43rd Annual J.P. Morgan Healthcare Conference ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectivelyFull Year 2025 ...

Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...